CliffBio
biologic

Ultomiris

ravulizumab-cwvz

Loss of exclusivityOctober 2032projected — 12-year biologic exclusivity estimate
CompanyAlexion Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameUltomiris
Active ingredientravulizumab-cwvz
Strength300MG/3ML (100MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalOctober 2020
Marketing statusRx

More from Alexion Pharmaceuticals

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.